Articles By Matthew Pillar

81. Engineering Antibodies To Suppress Severe Allergic Reactions 5/12/2022

    Dr. Jessica Grossman’s life’s work has been dedicated to women’s health, maternal health, family health, and inspiring the advance of female leadership in life sciences. She’s paving that path in her current role as CEO at IgGenix, which is pioneering genomically-engineered antibodies for the treatment of severe allergies.

82. How To Build A Genomic Medicine Biotech 5/11/2022

    SparingVision CEO Stephane Boissel took the reins of a fledgling, single-asset gene therapy company born of academic research and quickly built a well-funded startup with a deepening pipeline of ocular disease candidates. He told the Business of Biotech how it happened.

83. The CAR T Speed Show 5/9/2022

    Some mainstream, high-profile research out of the University of Pennsylvania has re-energized emerging cell therapy developers’ focus on manufacturing and administration speed. Speedy cell therapy pioneer EXUMA Biotech provides an update on its approach.

84. Gene Cargos: Building A Bigger Ship 5/6/2022

    Dissatisfied with the limitations of AAV gene editing, Drs. Ray Tabibiazar and Joe Higgins launched SalioGen, a company with an ambitious goal: the safe delivery of large strands of DNA cargo that mimics the way it happens in nature. 

85. Who Said mAbs Were Easy? 4/27/2022

    Under the leadership of CEO Mondher Mahjoubi, M.D., oncology-focused biotech Innate Pharma is developing therapeutic antibodies that harness the immune system to fight cancer. The company is making strides with some next-gen, complex tri- and tetra-specific antibodies—and Dr. Mahjoubi isn't afraid to face the CMC challenges that come with the job. 

86. Ocular + Auditory Cell Therapies: Lineage Cell Therapeutics 2.0 4/25/2022

    On the heels of a lucrative deal with Roche/Genentech for its Phase I/IIa dry age-related macular degeneration candidate, Lineage Cell Therapeutics is fording new waters with a promising auditory neuropathy spectrum disorder candidate. CEO Brian Culley shares the strategy.

87. CAR T-cell Therapy, Vaccines To Address Breast, Ovarian Cancers 4/20/2022

    In partnership with the Cleveland Clinic and Moffitt Cancer Centers, Anixa Biosciences moves into Phase 1 trials of its innovative approaches to treating and preventing all-too-prevalent cancers in women.

88. Building A Pipeline On Computational Biology 4/11/2022

    Fountain Therapeutics is building a pipeline of candidates aimed at reversing cellular aging. To inform the effort, it built an AI-driven computational platform capable of screening tens of thousands of compounds per month.

89. Coordinating Your International Regulatory Strategy 4/6/2022

    Aurion Biotech Chief Regulatory Officer Daniela Drago, Ph.D. is exercising an encyclopedic knowledge of regulatory harmonization as she navigates simultaneous clinical activity in the U.S., the E.U., and Japan. She shared insight into global regulatory frameworks and how to streamline them with BioProcess Online.

90. Venture Philanthropy Catalyzes T1D Therapeutic Development 3/25/2022

    Since the 1920s, the 1.6 million Americans living with type 1 diabetes have had one standard of care in insulin. But biologic therapy advances in the space are happening rapidly, thanks in large part to a unique venture philanthropy capital model.